You also can search for our most recent work on chimeric antigen receptor T-cell (CAR T) technologies using our tags here, or via our general search engine here. NIH CRADAs involving antigen receptor technologies. See this sheet. CAR patent litigation… Continue Reading
(More on government funded inventions here: https://keionline.org/government-funded-inventions) On December 9, 2016, the U.S. Army announced its intent to grant an exclusive license to Sanofi on patents for a U.S. Army-developed Zika vaccine. KEI and various other non-profit groups have filed… Continue Reading
(More on government funded inventions here) 2015 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015. 2015: NIH refuses to give information about principals in company seeking exclusive license to… Continue Reading
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.7 on the Global strategy and plan of action on public health, innovation and intellectual property either on Wednesday, 24 January 2018 or Thursday, 25 January 2018.… Continue Reading
On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading
In November 2017, the World Health Organization (WHO) published a report charting a path forward for the expansion of WHO’s work on the transparency of R&D costs and medicines prices while rekindling the prospects for WHO to assume the mantle of… Continue Reading
Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading